Citigroup’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,566
| Closed | -$290K | – | 6311 |
|
|
2025
Q4 | $290K | Buy |
8,566
+8,542
| +35,592% | +$265K | ﹤0.01% | 3830 |
|
|
2025
Q3 | $619 | Sell |
24
-2,111
| -99% | -$27.6K | ﹤0.01% | 5686 |
|
|
2025
Q2 | $17.1K | Sell |
2,135
-585
| -22% | -$4.46K | ﹤0.01% | 5112 |
|
|
2025
Q1 | $26.6K | Sell |
2,720
-247
| -8% | -$2.43K | ﹤0.01% | 5034 |
|
|
2024
Q4 | $37.5K | Buy |
2,967
+146
| +5% | +$1.85K | ﹤0.01% | 5150 |
|
|
2024
Q3 | $45.4K | Buy |
2,821
+906
| +47% | +$18.3K | ﹤0.01% | 5046 |
|
|
2024
Q2 | $46.7K | Buy |
1,915
+1,257
| +191% | +$58.1K | ﹤0.01% | 4621 |
|
|
2024
Q1 | $47.2K | Sell |
658
-4,241
| -87% | -$590K | ﹤0.01% | 4655 |
|
|
2023
Q4 | $974K | Sell |
4,899
-309
| -6% | -$38.3K | ﹤0.01% | 2844 |
|
|
2023
Q3 | $692K | Sell |
5,208
-362
| -6% | -$59.1K | ﹤0.01% | 2801 |
|
|
2023
Q2 | $833K | Sell |
5,570
-8,320
| -60% | -$1.3M | ﹤0.01% | 2980 |
|
|
2023
Q1 | $2.04M | Buy |
13,890
+3,139
| +29% | +$635K | ﹤0.01% | 2012 |
|
|
2022
Q4 | $1.7M | Buy |
10,751
+2,557
| +31% | +$409K | ﹤0.01% | 2169 |
|
|
2022
Q3 | $1.58M | Buy |
8,194
+3,860
| +89% | +$730K | ﹤0.01% | 2334 |
|
|
2022
Q2 | $633K | Buy |
4,334
+2,510
| +138% | +$334K | ﹤0.01% | 3038 |
|
|
2022
Q1 | $321K | Sell |
1,824
-6,766
| -79% | -$1.28M | ﹤0.01% | 3798 |
|
|
2021
Q4 | $2.52M | Buy |
8,590
+8,053
| +1,500% | +$2.15M | ﹤0.01% | 2428 |
|
|
2021
Q3 | $133K | Buy |
537
+198
| +58% | +$52.3K | ﹤0.01% | 4306 |
|
|
2021
Q2 | $86K | Buy |
339
+169
| +99% | +$31.6K | ﹤0.01% | 4575 |
|
|
2021
Q1 | $30K | Sell |
170
-269
| -61% | -$44.4K | ﹤0.01% | 5009 |
|
|
2020
Q4 | $69K | Buy |
439
+373
| +565% | +$81.1K | ﹤0.01% | 5817 |
|
|
2020
Q3 | $17K | Sell |
66
-120
| -65% | -$26.6K | ﹤0.01% | 6305 |
|
|
2020
Q2 | $43K | Buy |
186
+134
| +258% | +$20.7K | ﹤0.01% | 6115 |
|
|
2020
Q1 | $9K | Buy |
52
+13
| +33% | +$2.96K | ﹤0.01% | 7089 |
|
|
2019
Q4 | $8K | Buy |
+39
| New | +$7.18K | ﹤0.01% | 7275 |
|
Citigroup's RAPT Position: Q1 2026 in Review
Citigroup sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 8,566 shares — an estimated $290K sold.
Citigroup first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $2.52M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Citigroup reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 8,566 RAPT Therapeutics shares in Q1 2026, an estimated $290K.
- Citigroup first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- Citigroup's RAPT Therapeutics position peaked at $2.52M in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.